Strategic Move Marks a New Milestone in the Company's Rapid Growth. 

In a strategic move that underscores its commitment to global innovation and growth, CURA Diagnostics Inc. has announced the establishment of its second subsidiary company, CURA Diagnostics (Shenzhen) Co., Ltd., situated in the vibrant city of Shenzhen, China. This milestone comes after months of meticulous preparation, positioning CURA Diagnostics for heightened success and a transformative year in 2024.

This new subsidiary will play a pivotal role in collaborating with CURA Diagnostics Inc.'s manufacturer partners. By working closely with these partners, CURA Diagnostics (Shenzhen) Co., Ltd. aims to ensure the quality of products and efficient logistics. This collaborative effort encompasses a range of business activities, fostering a synergy that contributes to the overall success of CURA Diagnostics in the international market.

Dr. Jia He, CEO of CURA Diagnostics Inc., expressed her enthusiasm for this significant expansion, saying, "The establishment of CURA Diagnostics (Shenzhen) Co., Ltd. is a momentous step in our journey of growth and innovation. China is a key player in the global diagnostics market, and this subsidiary represents our commitment to delivering advanced diagnostics solutions to a broader audience. By working closely with our Chinese partners, we aim to enhance the efficiency and accessibility of our products."

CURA Diagnostics has been on a trajectory of rapid expansion since its inception, with milestones including the successful launch of its flagship product, Xpeedy DOA20, and a noteworthy over $2 million raised in a recent oversubscribed Seed Round. The establishment of CURA Diagnostics (Shenzhen) Co., Ltd. is a testament to the company's strategic vision, robust growth, and its commitment to providing cutting-edge diagnostic solutions worldwide.